日期 影响因子
日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:
–

Unexplained cause of thrombocytopenia, fever, anasarca and hypothyroidism: TAFRO syndrome with thrombotic microangiopathy renal histology

血小板减少、发热、全身水肿和甲状腺功能减退的病因不明：TAFRO综合征伴血栓性微血管病肾脏组织学

期刊:BMJ Case Reports
影响因子:0.5
doi:10.1136/bcr-2019-234155
Simeni Njonnou, Sylvain Raoul; Deuson, Justine; Royer-Chardon, Claire; Vandergheynst, Frédéric Alain; Wilde, Virginie De
心血管
甲状腺功能减退
血小板
免疫/内分泌
发表日期：2020
文献求助 收藏

Indirect treatment comparison of cabazitaxel for patients with metastatic castrate-resistant prostate cancer who have been previously treated with a docetaxel-containing regimen

对既往接受过含多西他赛方案治疗的转移性去势抵抗性前列腺癌患者进行卡巴他赛的间接治疗比较

期刊:PLoS One
影响因子:2.6
doi:10.1371/journal.pone.0195790
Fryzek, Jon P; Reichert, Heidi; Summers, Nicholas; Townes, Lindsay; Deuson, Robert; Alexander, Dominik D; Vanderpuye-Orgle, Jackie
前列腺癌
肿瘤免疫
肿瘤
发表日期：2018
文献求助 收藏

Cost effectiveness of romiplostim for the treatment of chronic immune thrombocytopenia in Ireland

罗米司亭治疗爱尔兰慢性免疫性血小板减少症的成本效益分析

期刊:Applied Health Economics and Health Policy
影响因子:3.3
doi:10.1007/s40258-013-0044-y
Lee, Dawn; Thornton, Patrick; Hirst, Alexander; Kutikova, Lucie; Deuson, Robert; Brereton, Nic
血小板
免疫/内分泌
发表日期：2013
文献求助 收藏

Erratum to: Cost Effectiveness of Romiplostim for the Treatment of Chronic Immune Thrombocytopenia in Ireland

勘误：爱尔兰罗米司亭治疗慢性免疫性血小板减少症的成本效益

期刊:Applied Health Economics and Health Policy
影响因子:3.3
doi:10.1007/s40258-014-0094-9
Carter, Marissa J; Lee, Dawn; Thornton, Patrick; Hirst, Alexander; Kutikova, Lucie; Deuson, Robert; Brereton, Nic
血小板
免疫/内分泌
发表日期：2013
文献求助 收藏